These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

412 related items for PubMed ID: 25446057

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Efficacy of endothelin blockade in adults with Fontan physiology.
    Derk G, Houser L, Miner P, Williams R, Moriarty J, Finn P, Alejos J, Aboulhosn J.
    Congenit Heart Dis; 2015; 10(1):E11-6. PubMed ID: 24890846
    [Abstract] [Full Text] [Related]

  • 3. The safety and effects of bosentan in patients with a Fontan circulation.
    Bowater SE, Weaver RA, Thorne SA, Clift PF.
    Congenit Heart Dis; 2012; 7(3):243-9. PubMed ID: 22348734
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. The effect of bosentan on exercise capacity in Fontan patients; rationale and design for the TEMPO study.
    Hebert A, Jensen AS, Idorn L, Sørensen KE, Søndergaard L.
    BMC Cardiovasc Disord; 2013 May 11; 13():36. PubMed ID: 23663658
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Endothelin inhibitors lower pulmonary vascular resistance and improve functional capacity in patients with Fontan circulation.
    Agnoletti G, Gala S, Ferroni F, Bordese R, Appendini L, Pace Napoleone C, Bergamasco L.
    J Thorac Cardiovasc Surg; 2017 Jun 11; 153(6):1468-1475. PubMed ID: 28283234
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Fontan circulation: the search for targeted therapy.
    Goldberg DJ, Paridon SM.
    Circulation; 2014 Dec 02; 130(23):1999-2001. PubMed ID: 25446056
    [No Abstract] [Full Text] [Related]

  • 11. Bosentan therapy for pulmonary arterial hypertension.
    Rubin LJ, Badesch DB, Barst RJ, Galie N, Black CM, Keogh A, Pulido T, Frost A, Roux S, Leconte I, Landzberg M, Simonneau G.
    N Engl J Med; 2002 Mar 21; 346(12):896-903. PubMed ID: 11907289
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Effect of Ambrisentan on Exercise Capacity in Adult Patients After the Fontan Procedure.
    Cedars AM, Saef J, Peterson LR, Coggan AR, Novak EL, Kemp D, Ludbrook PA.
    Am J Cardiol; 2016 May 01; 117(9):1524-32. PubMed ID: 27063478
    [Abstract] [Full Text] [Related]

  • 14. Effect of the oral endothelin antagonist bosentan on the clinical, exercise, and haemodynamic status of patients with pulmonary arterial hypertension related to congenital heart disease.
    Apostolopoulou SC, Manginas A, Cokkinos DV, Rammos S.
    Heart; 2005 Nov 01; 91(11):1447-52. PubMed ID: 15761050
    [Abstract] [Full Text] [Related]

  • 15. Bosentan induces clinical, exercise and hemodynamic improvement in a pre-transplant patient with plastic bronchitis after Fontan operation.
    Apostolopoulou SC, Papagiannis J, Rammos S.
    J Heart Lung Transplant; 2005 Aug 01; 24(8):1174-6. PubMed ID: 16102469
    [Abstract] [Full Text] [Related]

  • 16. Efficacy of Bosentan in patients after Fontan procedures: a double-blind, randomized controlled trial.
    Shang XK, Lu R, Zhang X, Zhang CD, Xiao SN, Liu M, Wang B, Dong NG.
    J Huazhong Univ Sci Technolog Med Sci; 2016 Aug 01; 36(4):534-540. PubMed ID: 27465329
    [Abstract] [Full Text] [Related]

  • 17. Drug therapy in the prevention of failure of the Fontan circulation: a systematic review.
    Oldenburger NJ, Mank A, Etnel J, Takkenberg JJ, Helbing WA.
    Cardiol Young; 2016 Jun 01; 26(5):842-50. PubMed ID: 26947621
    [Abstract] [Full Text] [Related]

  • 18. Impact of vitamin C on endothelial function and exercise capacity in patients with a Fontan circulation.
    Goldstein BH, Sandelin AM, Golbus JR, Warnke N, Gooding L, King KK, Donohue JE, Yu S, Gurney JG, Goldberg CS, Rocchini AP, Charpie JR.
    Congenit Heart Dis; 2012 Jun 01; 7(3):226-34. PubMed ID: 22176653
    [Abstract] [Full Text] [Related]

  • 19. Bosentan for treatment of inoperable chronic thromboembolic pulmonary hypertension: BENEFiT (Bosentan Effects in iNopErable Forms of chronIc Thromboembolic pulmonary hypertension), a randomized, placebo-controlled trial.
    Jaïs X, D'Armini AM, Jansa P, Torbicki A, Delcroix M, Ghofrani HA, Hoeper MM, Lang IM, Mayer E, Pepke-Zaba J, Perchenet L, Morganti A, Simonneau G, Rubin LJ, Bosentan Effects in iNopErable Forms of chronIc Thromboembolic pulmonary hypertension Study Group.
    J Am Coll Cardiol; 2008 Dec 16; 52(25):2127-34. PubMed ID: 19095129
    [Abstract] [Full Text] [Related]

  • 20. Effects of the endothelin receptor antagonist bosentan on hemodynamics and exercise capacity in Japanese patients with mildly symptomatic pulmonary arterial hypertension.
    Hatano M, Yamada H, Fukuda K, Yoshioka K, Funauchi M, Kuwana M, Sata M, Taniguchi M, Nakanishi N, Saito T, Saji T, Sasayama S.
    Heart Vessels; 2015 Nov 16; 30(6):798-804. PubMed ID: 25028167
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 21.